Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Cream

Chicago Study Looks At HIV Among Gay Men, Finds Many Unaware Of Status
More than 17 percent of gay men in Chicago have HIV, and 39 percent went untested in the last 12 months because of fear of the results, according to a study of nearly 600 gay men in the city by the Chicago Department of Health, the Chi-Town Daily News reports. The study also found that gay black men had an infection rate that was more than twice the rates of gay white and Hispanic men. Jim Pickett, director of advocacy for the AIDS Foundation of Chicago, said the findings indicate that, "We need to incorporate HIV into a broader or more holistic framework (covering) gay men"s health needs from top to toe." The city will formally release the study"s results next week (Parker, Chi-Town Daily News, 6/2).
generic viagra online
Link Between Pressure To Look Attractive And Fear Of Rejection In Men And Women
People who feel pressure to look attractive are more fearful of being rejected because of their appearance than are their peers, according to a new study by researchers at the University at Buffalo and the University of Kent. Drugshop to buy zoloft online and other pills.
News of the day
Chance Of Fetal Complications Following Accidents Not Increased By Automobile Restraints
It is well established that seat belts save lives. However, many pregnant women do not wear seat belts, for fear that the belt itself could injure the baby in a car crash. But is this actually the case? Does the seat belt put the baby at risk?
Public Health

Agios Pharmaceuticals' Focus Of Drug Research - Cancer Metabolism - Selected For Stand Up To Cancer Grant

Agios Pharmaceuticals today announced that Stand Up To Cancer (SU2C), a charitable initiative for new cancer treatments, has selected the Cancer Metabolism "dream team" led by Agios founder Dr. Craig Thompson and including Agios advisors Drs. Chi Dang and Joshua Rabinowitz. Cancer Metabolism is one of only five research areas chosen to share in $73.6 million in translational research funding, based on a rigorous selection process by independent scientific advisors assembled by SU2C"s scientific partner, the American Association for Cancer Research (AACR). Cancer metabolism is a new and exciting field of biology that represents a breakthrough understanding of how cancer cells become addicted to using more nutrients than normal cells to ensure their survival and growth. This new understanding of a fundamental mechanism of cancer represents a powerful Achilles" heel to target this deadly disease. With the help of Craig Thompson, MD, Chi Dang, MD, and other key advisors including Lewis Cantley, PhD, and Tak Mak, PhD, Agios was founded a year ago to lead the translation of cancer metabolism biology and decades of metabolic biochemistry into novel cancer therapeutics that will make a difference for patients. In its first year of operation, Agios has taken a leadership position in the field of Cancer Metabolism with more than 40 employees and a rapidly emerging drug pipeline. Yesterday, Agios announced the appointment of its new leadership team to further lead and grow the vision of Agios. David Schenkein, MD, of Genentech will assume his role as Chief Executive Officer in August and Duncan Higgons, formerly of Archemix, became the Chief Operating Officer in May. "It is great to see Stand Up To Cancer and AACR recognize and further validate the therapeutic potential of Cancer Metabolism which has been the driving vision behind building Agios over the past year," said David Schenkein, incoming Chief Executive Officer of Agios Pharmaceuticals. "The progress to date of Agios has been impressive, bringing together great people, a passionate culture, deep science and an emerging pipeline of novel drugs that is leading the field rapidly downstream towards the clinic." Stand Up To Cancer worked in collaboration with the American Association for Cancer Research (AACR) to identify and fund "dream teams" in areas of cancer research that provide the most promising near term potential breakthrough therapies for patients. Cancer Metabolism was selected as one of the five research areas to receive SU2C research grants, based on the recommendation of a scientific advisory committee assembled by AACR. The Cancer Metabolism dream team includes four elite scientists, three of whom are key Agios founders and advisors: - Co-Leader - Agios Co-Founder Craig B. Thompson, M.D., Director, Abramson Cancer Center, University of Pennsylvania. - Principal Reseacher - Agios Advisor Chi Van Dang, M.D., Ph.D., Vice Dean for Research of Johns Hopkins University School of Medicine. - Principal Researcher - Agios Advisor Joshua D. Rabinowitz, M.D., Ph.D., Assistant Professor of Chemistry and Integrated Genomics, Princeton University. Agios Pharmaceuticals


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009